For patient information about Tivicay, please refer to the consumer information leaflet (CMI) available on the Medsafe website.
# Sometimes Tivicay must be taken twice a day; talk to your doctor if this applies to you *tenofovir/emtricitabine for full Consumer Medicine Information refer to www.medsafe.govt.nz
References: 1. Tivicay (dolutegravir) Consumer Medicine Information GSK NZ November 2017 2. Pharmaceutical Schedule December 2016, PHARMAC
TIVICAY ® (dolutegravir sodium), 50 mg film-coated tablets, is a Prescription Medicine that works as an integrase inhibitor, used for the treatment of Human Immunodeficiency Virus (HIV) infection in combination with other anti HIV agents in adults and children over 12 years of age and weighing 40kg or more. TIVICAY has risk and benefits and should only be prescribed by a doctor experienced in treating HIV. Ask your Doctor if TIVICAY is right for you. Use strictly as directed. If you have concerns or if you have side effects, see your doctor, pharmacist or healthcare professional. TIVICAY is a funded medicine; Special Authority criteria apply. Normal doctor’s consultation fees apply. You can view full Consumer Medicine Information at www.medsafe.govt.nz. TIVICAY is a registered trade mark of the ViiV Healthcare group of companies, marketed on behalf of ViiV Healthcare by GlaxoSmithKline NZ Limited, Auckland. Adverse events involving ViiV Healthcare products should be reported to ViiV Healthcare Medical Information on 0800 808 500.